QQ客服 官方微博 反馈留言

浏览/检索结果: 共4条，第1-4条 帮助 已选(0)清除 条数/页：5101520253035404550556065707580859095100   排序方式：请选择作者升序作者降序题名升序题名降序发表日期升序发表日期降序提交时间升序提交时间降序 LUX-Lung 6: A randomized, open-label, phase III study of afatinib (A) versus gemcitabine/cisplatin (GC) as first-line treatment for Asian patients (pts) with EGFR mutation-positive (EGFR M plus ) advanced adenocarcinoma of the lung. 期刊论文 JOURNAL OF CLINICAL ONCOLOGY, 2013, 卷号: 31, 期号: 15 作者:  Wu, Yi Long;  Zhou, Caicun;  Hu, Cheng-Ping;  Feng, Ji Feng;  Lu, Shun 收藏  |  浏览/下载：3/0  |  提交时间：2019/12/04 LUX-Lung 6: Patient-reported outcomes (PROs) from a randomized open-label, phase III study in first-line advanced NSCLC patients (pts) harboring epidermal growth factor receptor (EGFR) mutations 期刊论文 JOURNAL OF CLINICAL ONCOLOGY, 2013, 卷号: 31, 期号: 15 作者:  Geater, Sarayut Lucien;  Zhou, Caicun;  Hu, Cheng-Ping;  Feng, Ji Feng;  Lu, Shun 收藏  |  浏览/下载：1/0  |  提交时间：2019/12/04 LUX-Lung 6: A randomized, open-label, phase III study of afatinib (A) versus gemcitabine/cisplatin (GC) as first-line treatment for Asian patients (pts) with EGFR mutation-positive (EGFR M plus ) advanced adenocarcinoma of the lung. 期刊论文 JOURNAL OF CLINICAL ONCOLOGY, 2013, 卷号: 31, 期号: 15 作者:  Hou, Mei;  Wu, Yi Long;  Zhou, Caicun;  Hu, Cheng-Ping;  Feng, Ji Feng 收藏  |  浏览/下载：7/0  |  提交时间：2019/12/05 LUX-Lung 6: Patient-reported outcomes (PROs) from a randomized open-label, phase III study in first-line advanced NSCLC patients (pts) harboring epidermal growth factor receptor (EGFR) mutations 期刊论文 JOURNAL OF CLINICAL ONCOLOGY, 2013, 卷号: 31, 期号: 15 作者:  Geater, Sarayut Lucien;  Zhou, Caicun;  Hu, Cheng-Ping;  Feng, Ji Feng;  Lu, Shun 收藏  |  浏览/下载：3/0  |  提交时间：2019/12/05